Celestia S. Higano
Fred Hutchinson Cancer Research Center
465 Papers
3.4K Citations
Celestia S. Higano is an academic researcher from Fred Hutchinson Cancer Research Center. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 78, co-authored 423 publications. Previous affiliations of Celestia S. Higano include United States Department of Veterans Affairs & Ohio State University.
Chat about Author
Papers
Circulating tumor cells (CTC) and prostate specific antigen (PSA) as response indicator biomarkers in chemotherapy-naïve patients with progressive castration-resistant prostate cancer (CRPC) treated with MDV3100.
Aseem Anand,Howard I. Scher,Tomasz M. Beer,Celestia S. Higano,Daniel C. Danila,M. Taplin,Eleni Efstathiou,M. Hirmand,Charles L. Sawyers,G. Heller +9 more
TL;DR: The availability of reliable indicators of treatment efficacy is a critical unmet need in drug development for CRPC and MDV3100 is a second-generation oral androgen receptor antagonis...
6
767presponse rates and outcomes with enzalutamide for patients with metastatic castration resistant prostate cancer and visceral disease in the prevail trial
Celestia S. Higano,Joshi J. Alumkal,Simon Chowdhury,Yohann Loriot,Cora N. Sternberg,J.S. de Bono,Bertrand Tombal,Joan Carles,Frank Perabo,David Forer,Sarah B. Noonberg,Harry H. Mansbach,Tomasz M. Beer +12 more
TL;DR: The results support androgen receptor signaling as an important target in prostate cancer with visceral metastases in men with chemotherapy-naive men with asymptomatic or mildly symptomatic mCRPC.
6
Sexual Health After Cancer Therapy.
TL;DR: It is concluded that patients should be referred to urologists for treatment of cancer-related ED and how surgery, radiation, chemotherapy, and hormonal therapy can cause ED, dry ejaculation, climacturia, or anorgasmia.
6
New Developments in the Treatment of Castration-Resistant Prostate Cancer
TL;DR: The rationale behind therapeutic decisions and the supporting clinical trial data are explored, and the different classes of therapeutic agents, from immunotherapy and hormonal therapies to chemotherapy and radioisotopes, are reviewed and offered suggestions for the clinical scenarios in which they may be used most successfully.
Pd24-12 overall survival analysis of african american and caucasian patients receiving sipuleucel-t: preliminary data from the proceed registry
A. Oliver Sartor,Andrew J. Armstrong,Chiledum Ahaghotu,David G. McLeod,Matthew R. Cooperberg,David F. Penson,Philip W. Kantoff,Nicholas J. Vogelzang,Arif Hussain,Christopher Pieczonka,Nancy N. Chang,Celestia S. Higano +11 more
TL;DR: A multimodal treatment strategy inclusive of the NED endpoint for patients who present with disease that is beyond the limits of curability by any single modality should be considered to enable the evaluation of new approaches in order to prioritize large-scale testing in early stages of advanced disease.
5